Clinical trial readout dates for NewAmsterdam Pharma Company N.V., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is November 2027.
| Phase 3 obicetrapib 10 mg + ezetimibe 10 mg FDC daily Lipidemia; Coronary Artery Disease · NCT06305559 | November 2027 Ongoing |
| Phase 3 obicetrapib 10 mg + ezetimibe 10 mg FDC daily Lipidemia; Type 2 Diabetes (T2DM) · NCT07219602 | March 2028 Ongoing |
| Phase 2 Obicetrapib 10 mg Preclinical Alzheimer's Disease · NCT07794670 | September 2028 Recruiting |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 2 obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks Dyslipidemias · NCT06496243 | November 2026 Recruiting |
| Phase 3 Obicetrapib Atherosclerotic Cardiovascular Disease · NCT05202509 | November 2026 Ongoing |
NewAmsterdam Pharma Company N.V. reported $643M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $17M; at that rate the cash would last about 37 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.